BrainsWay Ltd. (NASDAQ & TASE: BWAY) and its subsidiary BrainsWay USA, Inc., a global leader in the advanced non-invasive treatment of brain disorders, today announced that its Board of Directors has decided to appoint Christopher von Jako, Ph.D., as President and Chief Executive Officer (CEO). Dr. von Jako’s appointment cements the Board's commitment to a strategic transition to U.S.-based leadership, and will become effective in January 2020. “Dr. von Jako is a science-driven senior executive with over 25 years of experience managing businesses and leading global medical technology companies,” said Dr. David Zacut, a co-founder of BrainsWay and Chairman of the Board, who has been serving as Interim CEO since September 2019.
Greenbrook TMS NeuroHealth Centers, a leading provider of Transcranial Magnetic Stimulation (TMS) in the United States, is now offering BrainsWay’s Deep TMS Therapy for obsessive-compulsive disorder (OCD) in facilities around the St. Louis area, which includes Greenbrook TMS - Creve Couer and Greenbrook TMS - O’Fallon. The company has already been treating patients with major depressive disorder (MDD) using Deep TMS at their facilities across the country.
BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced noninvasive treatment of brain disorders, today announced the launch of #StandAgainstTheStigma, a sweepstakes dedicated to raising awareness and sparking conversation around mental health. The campaign will encourage people to share their stories, tips and experiences with mental illness throughout the month of May, in observance of Mental Health Awareness Month.
BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay”), a global leader in the advanced non-invasive treatment of brain disorders, today announced that Dr. Christopher von Jako, Chief Executive Officer, will participate in the upcoming investor conferences. BrainsWay is a commercial stage medical device company focused on the development and sale of non-invasive neuromodulation products using the Company’s proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology for the treatment of major depressive disorder (MDD) and obsessive compulsive disorder (OCD), for which BrainsWay received marketing authorization from the U.S. Food and Drug Administration (FDA) in 2013 (for MDD) and in August 2018 (for OCD). BrainsWay is currently conducting clinical trials of Deep TMS in other psychiatric, neurological and addiction disorders.
Greenbrook TMS NeuroHealth Centers, one of the leading providers of Transcranial Magnetic Stimulation (TMS) therapy in the United States, announced today that it is now offering BrainsWay’s Deep TMS therapy for patients with obsessive-compulsive disorder (OCD) at its Greenbrook - Cary facility in North Carolina. “We are eager to offer BrainsWay’s Deep TMS helmet as an option for patients with OCD in Raleigh and Durham, especially for those who find themselves resistant to traditional forms of treatment,” said Dr. Kellie Tolin, regional medical director of North Carolina for Greenbrook TMS.
Solace Behavioral Health, a mental health clinic offering advanced treatments for mental health disorders, announced today that it will host an grand opening to formally introduce its latest treatment offering, BrainsWay’s Deep Transcranial Magnetic Stimulation (Deep TMS) for major depressive disorder (MDD) and obsessive-compulsive disorder (OCD). “For the last six years we have provided high-quality mental health services to the Brooksville community,” said Tanveer Chaudhry, M.D., psychiatrist at Solace Behavioral Health.
BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced non-invasive treatment of brain disorders, today announced a preliminary, unaudited revenue range for the first quarter ended March 31, 2020. Specifically, the Company expects first quarter revenues to be within the range of $3.9 million to $4.2 million. “Our revenue estimate for the first quarter reflects the impact that the COVID-19 global health pandemic is having on our business,” said Christopher von Jako, Ph.D., President and Chief Executive Officer of BrainsWay.
BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay”) today announced interim results from a multicenter randomized controlled double-blind clinical trial assessing the safety and efficacy of the Company’s H7-coil deep transcranial magnetic stimulation (dTMS) System for the treatment of adults with post-traumatic stress disorder (PTSD). Results showed that the H7 dTMS, which targets the medial prefrontal cortex (mPFC), did not demonstrate sufficient efficacy relative to sham control treatment in PTSD patients. Based on the interim analysis, the Company will not invest additional resources in order to continue this study.
BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay”), a commercial stage medical device company focused on the development and sale of non-invasive neuromodulation producats using the Company’s proprietary Deep Transcranial Magnetic Stimulation (dTMS) technology for the treatment of major depressive disorder (MDD) and Obsessive Compulsive Disorder (OCD), announced today that Mr. Avner Lushi will be joining its board of directors and will also serve as a member of its audit committee. The announcement comes after the recent shareholder approval of his election to the board.
JERUSALEM, Israel and HACKENSACK, N.J., Nov. 25, 2019 -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced non-invasive.
BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced non-invasive treatment of brain disorders, today announced that it will report its Fourth Quarter and Full-Year 2019 Financial Results and Operational Highlights on March 23, 2020. The Company will host a conference call at 8:30 AM Eastern Time to review the financial results and operational highlights. The conference call will be broadcast live and will be available for replay for 30 days on the Company's website, https://investors.brainsway.com/financial-calendar .Please access the Company's website at least 10 minutes ahead of the conference call to register.
Results demonstrate increased activity in attention-related brain networks treated with BrainsWay’s H6-coil, which correlate with observed improvement in ADHD symptoms.
The Remedy, a person-centered mental health care facility offering advanced treatments, announced today that it is now offering BrainsWay’s Deep Transcranial Magnetic Stimulation (Deep TMS) for major depressive disorder (MDD) and obsessive-compulsive disorder (OCD). “Our mission at The Remedy is to provide the best treatment options available in one place, for patients with mental health illnesses in the Vadnais Heights community,” said Dr. Jeffrey Sawyer, M.D., psychiatrist, co-founder and CEO of The Remedy.
BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced non-invasive treatment of brain disorders, today announced that Hadar Levy has been promoted to Senior Vice President and General Manager of North America, and Judith Huber has been appointed the Company’s Senior Vice President and Chief Financial Officer, effective May 11, 2020. Mr. Levy will oversee BrainsWay’s North American business, including sales, operations, customer service, field engineering, and customer training.
NEW YORK, NY / ACCESSWIRE / March 23, 2020 / Brainsway Ltd. (NASDAQ:BWAY) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 23, 2020 at 8:30 AM Eastern ...
PATTERSON, N.J., March 23, 2020 -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced non-invasive treatment of brain.
PRESCOTT VALLEY, Ariz., Feb. 06, 2020 -- West Yavapai Guidance Clinic, a non-profit mental health facility offering advanced treatments for behavioral and mental health.
BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay”) today announced final positive results from its pivotal multicenter trial assessing the safety and efficacy of the Company’s H4 Deep transcranial magnetic stimulation system (Deep TMS) as an aid in smoking cessation in adults suffering from chronic smoking addiction. This trial represents the first multicenter pivotal study conducted with any non-invasive brain stimulation device in the addiction space.
Greenbrook TMS NeuroHealth Centers, one of the leading providers of mental health services in the United States, is now offering BrainsWay’s Deep Transcranial Magnetic Stimulation (Deep TMS) therapy for patients with obsessive-compulsive disorder (OCD) at their Newport News location in Virginia. “We’re proud to announce that Greenbrook TMS is now offering BrainsWay’s Deep TMS device for OCD across our offices in Virginia, with the latest being Newport News,” said Dr. William Sauve, regional medical director of Virginia for Greenbrook TMS.
BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced non-invasive treatment of brain disorders, today announced the appointment of Christopher Boyer as Vice President of Global Marketing. Mr. Boyer will be responsible for worldwide marketing activities with a focus on expanding BrainsWay’s market share, leading the corporate go-to-market strategy, and overseeing the continued development of the BrainsWay brand.